CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Influenza A H3N2 virus dose arm 1 +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06613737
NCT06613737N/ACompleted

An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age

Hvivo·interventional·Posted Sep 26, 2024·Updated Apr 23, 2026

In Brief

A clinical study evaluating Influenza A H3N2 virus dose arm 1, Influenza A H3N2 virus dose arm 2, and 1 other intervention for Influenza A H3N2. Completed, enrolled 33 participants across 1 site.

Detailed Summary

An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age In Part A, up to 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2). Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedSep 26, 2024
Enrollment StartSep 11, 2024
Primary CompletionMar 10, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 1.8 years ago

Interventions

Influenza A H3N2 virus dose arm 1other

Medium dose, approximately 10\^4.5 TCID50/mL

Influenza A H3N2 virus dose arm 2other

High dose, approximately 10\^5.5 TCID50/mL

Influenza A H3N2 virus dose arm 3other

TBD, depending on outcome of Part A